Pfizer and BioNTech have commenced the dosing of participants in a Phase I/II clinical trial assessing the BNT162 vaccine candidate to protect against Covid-19 in the US.
The study is part of a global development programme and the dosing of initial participants in Germany was concluded last week.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
During the Phase I/II protocol, the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates will be assessed in a single, continuous study. The trial’s dose level escalation part in the US will involve up to 360 healthy participants.
